Pacific Horizon: Encouraging Mutations in the Venture Model
• By Chris Morrison
Pacific Horizon is an active venture investor, often owning large majority stakes in its portfolio companies. The venture capitalist has taken two different strategies with its majority-owned virology investments, Illumigen and Koronis, eschewing and embracing risk, respectively. Each firm, however, represents a potential game-changing opportunity, and illustrates PHV's back-to-basics venture philosophy: making novel-mechanism bets that are perceived as having both high scientific risks and long-term potential paybacks
By Christopher Morrison
Donald Elmer, the interim CEO of Koronis Pharmaceuticals Inc. and the managing general partner of Seattle-based VC Pacific Horizon Ventures, views the world of venture investing much like the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.
Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now
Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.
Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.
Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.
